Cell Reports, Volume 34

Supplemental Information

MDA5 Governs the Innate Immune Response

to SARS-CoV-2 in Lung Epithelial Cells

Xin Yin, Laura Riva, Yuan Pu, Laura Martin-Sancho, Jun Kanamune, Yuki Yamamoto, Kouji Sakai, Shimpei Gotoh, Lisa Miorin, Paul D. De Jesus, Chih-Cheng Yang, Kristina M. Herbert, Sunnie Yoh, Judd F. Hultquist, Adolfo García-Sastre, and Sumit K. Chanda

MOI



MOI

MOI

В

MOI

Figure S1: The innate immune response in Calu-3 cells upon stimulation (related to Figure 1). (A) Calu-3 cells were either transfected with poly IC (5 µg/mL) or 3p-hpRNA (2.5 µg/mL) or were infected with 100 hemagglutinin units/ml of Sendai virus (SeV) for activation of MDA5 and RIG-I signaling. After 6h or 12 h, the intracellular mRNA was extracted for quantification of mRNA levels of IFNs, ISGs, and proinflammatory cytokines by qRT-PCR. Data are expressed as fold changes relative to mock transfected cells and the results show the mean ± SEM of three independent experiments. (B) Calu3 cells were infected with equal amount (100 GE/cell) of Sendai virus and SARS-CoV-2, the cells were collected for quantification of IFN- β and viral mRNAs by gRT-PCR at the indicated time points. (C) Kinetics of IFN secretion responses in infected cells. Concentrations of IFN-β and IFN- λ in the culture supernatants were measured by specific ELISA, respectively. The results show the mean ± SEM of the average of the duplicates in each of 2 independent experiments. (D) The kinetics for the expression of mRNAs encoding different ISGs upon SARS-COV-2 infection of Calu-3 cells are shown. Data are expressed as fold change relative to mock-infected cells. (E) Calu-3 cells infected with SARS-CoV-2 at an MOI of 1.0 for 48 hours were treated with either IFN β (100 IU) or IFN λ 1 (1000 IU) for 3 hours prior to detection of protein expression with specific antibodies. (F) Calu-3 cells (1x10⁵) were infected with SARS-CoV-2 at the indicated MOI in the presence of remdesivir for 48 hours. The induction of ISGs and proinflammatory cytokines was quantified by gRT-PCR. Data are expressed as fold change relative to mock-infected cells.





В



С



Figure S2: Characterization of iPSC-derived airway epithelial cell model (related to Figure 2). (A) Immunofluorescent analysis of iPSC-derived airway epithelial cells by confocal microscopy. Nuclei were counterstained with DAPI. Acetylated tubulin (Ac-TUB) + ciliated cells and MUC5B+ mucus producing cells were observed. Expression of cystic fibrosis transmembrane conductance regulator (CFTR) was recognized on the apical side of ciliated cells. (B) Representative immunofluorescent images of iPSC-derived airway epithelial cells for quantification of each markers. FoxJ1(Red), a marker for ciliated cells, MUC5B (Red, a marker for goblet cells), p63 (Green, a marker for basal cells), CHGA (Red, a marker for neuroendocrine cells). CCSP (Orange, a marker for club cells). Scale bars, 100 μ m. (C) 3D imaging analysis showed enriched expression of ACE2 and TMPRSS2 on iPSC-derived airway epithelial cells. Expression of ACE2 was localized on the apical side of cells, whereas localization of TMPRSS2 on both apical and lateral side of cells.

DMSO Remdesivir(5µM) 60 \ 0 % Infected cells 40-20-÷ ш 0 5 1 MOI

NP positive cells

ç

0.2



















D

А

Figure S3: The IFN response in iPSC-derived airway epithelial cells infected with SARS-CoV-2 (related to Figure 2).

(A) The percentage of infection was calculated as the ratio between the number of infected cells stained for SARS-CoV-2 NP and the total amount of cells stained with DAPI. Data are from three technical replicates. (B-D) The induction of IFN, ISG and proinflammatory cytokines was quantified by qRT-PCR in SARS-CoV-2 infected iPS cell–derived airway epithelium. Data are expressed as fold change relative to mock-infected cells from three independent experiments with two technical replicates.



Figure S4: The antiviral effect of exogenous and endogenous IFNs (related to Figure 3). (A) Inhibition of SARS-CoV-2 replication in Calu-3 cells by IFN β and IFN λ . Calu-3 cells were pretreated with IFN β or IFN λ at indicated concentration for 2 hours prior to infection. After treatment, the cells were infected with SARS-CoV-2 at an MOI of 0.625 for 48 hours. Cells were fixed, and immunostained with rabbit-anti-SARS-CoV-2 NP antibody, and imaged with the Celigo high content imager. Results from duplicate experiments are presented with bars representing standard deviations. (B) The viral RNA in supernatants collected from the infected cells was quantified by qRT-PCR using primers targeting the N2 regions. Data are from three independent experiments with two technical replicates.

Sc

DDX3X

DDX60

RIG-

DHX9

ZNFX1

А

DDX1

DHX36

MAVS

В

Viral titer (log₁₀ PFU/mL)



Е





D

LGP2

DDX21

NOD

IDA5

DHX15

TLR3

LRRFIP1

É.

DHX33

NOD2





Figure S5: MDA5/LGP2 are the dominant RNA sensors responsible for innate immune induction in Calu-3 cells infected with SARS-CoV-2 (related to Figure 4). (A) Representative immunofluorescence images from Figure 4C are shown. Scale bar, 100 μ m. (B) Viral titer in the supernatants collected from infected cells (Figure 4C) were determined by plaque assay in vero E6 cells. Data show mean ± SD from one representative experiment in triplicate (n=3). (C-D) The cells were either infected with SeV or transfected with poly IC (5 μ g/mL). Cells were lysed 20 h after SeV infection or 8 h after poly IC transfection for IFN- β mRNA quantification. Data are presented as fold changes relative to non-treated cells. (E) The supernatants were collected from the infected cells at 48 h.p.i. Viral titer in the collected supernatants were determined by plaque assay in vero E6 cells. Data show mean ± SD from one representative experiment in triplicate (n=3).

А

Scr TBK1 IFF7 RELA





С



Figure S6: IRF3, IRF5, and p65 are required for the IFN signaling transduction in response to SARS-CoV-2 infection (related to Figure 5). (A) Representative immunofluorescence images from Figure 5C are shown. Scale bar, 100 μ m. (B) Viral titer in the collected supernatants were determined by plaque assay in vero E6 cells. 100 μ L of virus-containing supernatants that were serially diluted 1:10 for inoculation in vero E6 cells. Plaques were quantified and recorded as PFU/mL. Data show mean ± SD from one representative experiment in triplicate (n=3). (C) Confocal images showing viral NP and dsRNA in Calu-3 cells infected with SARS-CoV-2 at MOI of 1. Cells were stained 48 hours after infection with a rabbit anti-SARS-CoV-2 NP antibody, and anti-dsRNA [rJ2] antibody, DAPI was used to stain the nuclei. Scale bar, 10 μ m.

Gene name	Sequence (5'-3')
RIG-I	F: CACCTCAGTTGCTGATGAAGGC
	R: GTCAGAAGGAAGCACTTGCTACC
MDA5	F: GCTGAAGTAGGAGTCAAAGCCC
	R: CCACTGTGGTAGCGATAAGCAG
LGP2	F: ATGACCACCTGGAGATGCCTGA
	R: CATTGTAGCGCCTCAGGTGAAG
LRRFIP1	F: GAGAGACTTCCGACACCCTCAA
	R: CACCTCCACTTCACTGGCTCTT
DDX1	F: AAACCAAGCCCTCTTTCCTGCC
	R: GCCTTGGAAAGAGCAACAAAGCC
DDX3	F: ACTATGCCTCCAAAGGGTGTCC
	R: AGAGCCAACTCTTCCTACAGCC
DHX9	F: AGCTGTGGCTACAGCGTTCGAT
	R: CTGATTCCTCGAATGCCTGCTTC
DHX15	F: CACTGCTGAACGTCTACCATGC
	R: CATTGTCTGCGGACATCAGGGA
DDX21	F: TGGACTCAGAGGGCAGCAGTTA
	R: TGTCTCCATGCAAGGACTGAGC
DHX33	F: GAGAGGACAGTGGCATCTGCTA
	R: GAAGCTGAAGCATCACACTGGC
DHX36	F: CCCACCATCAAATGAGGCAGTG
	R: TGTGGCTCAACGGGTAATCGTG
DDX60	F: GGTGTTTTCACCAGGGAGTATCG
	R: CCAGTTTTGGCGATGAGGAGCA
ZNFX1	F: TGAGACTCCAGGAAGACCTGCA
	R: ACAATCCTCGGCTCCACCTTCT
TLR3	F: GCGCTAAAAAGTGAAGAACTGGAT
	R: GCTGGACATTGTTCAGAAAGAGG
NOD1	F: CAACGGCATCTCCACAGAAGGA
	R: CCAAACTCTCTGCCACTTCATCG
NOD2	F: GCACTGATGCTGGCAAAGAACG
	R: CTTCAGTCCTTCTGCGAGAGAAC
MAVS	F: ATGGTGCTCACCAAGGTGTCTG
TBK1	

Table S1. The primers used for qPCR in this study. Related to STAR Methods

IRF1	F: GAGGAGGTGAAAGACCAGAGCA	
	R: TAGCATCTCGGCTGGACTTCGA	
IRF3	F: TCTGCCCTCAACCGCAAAGAAG	
	R: TACTGCCTCCACCATTGGTGTC	
IRF5	F: TATGCCATCCGCCTGTGTCAGT	
	R: GCCCTTTTGGAACAGGATGAGC	
IRF7	F: CCACGCTATACCATCTACCTGG	
	R: GCTGCTATCCAGGGAAGACACA	
RELA/p65	F: TGAACCGAAACTCTGGCAGCTG	
	R: CATCAGCTTGCGAAAAGGAGCC	
IFNA1	F: GCCTCGCCCTTTGCTTTACT	
	R: CTGTGGGTCTCAGGGAGATCA	
IFNB1	F: ATGACCAACAAGTGTCTCCTCC	
	R: GGAATCCAAGCAAGTTGTAGCTC	
IFNL1	F: GTGACTTTGGTGCTAGGCTTG	
	R: GCCTCAGGTCCCAATTCCC	
IFNL2/3	F: AGTTCCGGGCCTGTATCCAG	
	R: GAGCCGGTACAGCCAATGGT	
IFNL4	F: CGATCCTGGAGCTGCTG	
	R: TTTGTGACGCCTCTTCTGG	
CXCL10	F: GTGGCATTCAAGGAGTACCTC	
	R: GCCTTCGATTCTGGATTCAGACA	
ISG15	F: GGCTGGGAGCTGACGGTGAAG	
	R: GCTCCGCCCGCCAGGCTCTGT	
IFIT1	F: AAGCTTGAGCCTCCTTGGGTTCGT	
	R: TCAAAGTCAGCAGCCAGTCTCAGG	
IFIT2	F: CAG CTGAGAATTGCACTGCAA	
	R: GTAGGCTGCTCTCCAAGG AA	
IFITM1	F: CCAAGGTCCACCGTGATTAAC	
	R: ACCAGTTCAAGAAGAGGGTGTT	
IL6	F: AGACAGCCACTCACCTCTTCAG	
	R: TTCTGCCAGTGCCTCTTTGCTG	
IL-1β	F: AAGCTGATGGCCCTAAACAG	
	R: AGGTGCATCGTGCACATAAG	
IL8	F: GAGAGTGATTGAGAGTGGACCAC	
	R: CACAACCCTCTGCACCCAGTTT	
GAPDH	F: CATGAGAAGTATGACAACAGCCT	
	R: AGTCCTTCCACGATACCAAAGT	